Goodwin Advises Absci on the Collaboration and $20 Million Strategic Investment With AMD to Accelerate the Future of AI Drug Discovery
January 11, 2025
January 11, 2025
BOSTON, Massachusetts, Jan. 11 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Absci Corporation on a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. AMD made a $20 million investment in Absci, structured as a private investment in public equity, underscoring the growing demand for inno . . .
The Life Sciences team advised Absci Corporation on a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. AMD made a $20 million investment in Absci, structured as a private investment in public equity, underscoring the growing demand for inno . . .